Assays
Not all pap tests are created equal
The BD SurePath™ Liquid-based Pap Test ensures fewer unsatisfactory results than other methods1,2 and increases HSIL+detection,3 leading to fewer missed cases of invasive cervical cancer4
BD SurePath™ Liquid-based Pap Test
Learn more about the BD SurePath™ collection vial and the BD SurePath™ Liquid-based Pap Test
Offering accuracy from collection to result
The BD SurePath™ Liquid-based Pap Test is your trusted partner for reliable sample collection and accurate result reporting
- The BD SurePath™ collection vial is designed to improve patient care over conventional pap by providing physicians with the convenience of a single-source collection Pap screening and molecular diagnostic testing
- The BD SurePath™ Liquid-based Pap Test and the BD Onclarity™ HPV Assay provide HPV primary screening, co-testing and cytology primary with ASCUS reflex
- When used with the BD Totalys™ MultiProcessor, the BD SurePath™ collection vial 2D barcodes allow Positive Sample Identification from collection through cytological and molecular testing, providing confidence in the results
- The BD SurePath™ Liquid-based Pap Test can be processed according to the throughput and the automation levels needed. BD Totalys™ MultiProcessor or BD PrepMate™ (sample preparation, including cell enrichment), BD Totalys™ SlidePrep (slide preparation and staining) and BD FocalPoint™ GS Imaging System (slide analysis)
Standardized sample collection
Accurate result reporting
* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916. 2. Fontaine D et al. BMJ Open. 2012;2(2):e000847. 3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279. 4. Rozemeijer K et al. BMJ. 2017;356:j504. 5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174. 6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153. 7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31
Reduce unsatisfactory results
Due to the unique cell enrichment method, the BD SurePath™ Liquid-based Pap Test exhibits lower unsatisfactory rates compared to conventional cytology and the ThinPrep™ Pap Test
- Unsats represent a missed opportunity for screening and are more often associated with cervical abnormality2
Leading causes of unsatisfactory samples include:1
Insufficient number of squamous cells
With BD SurePath™ Liquid-based Pap Test, the head of the collection device is deposited directly into the BD SurePath™ collection vial, so 100% of the sample is sent to the laboratory – unlike the rinse-and-swirl technique, which can result in an average of 37% of the cells being discarded5
Obscuring blood and inflammation
The BD SurePath™ Liquid-based Pap Test removes debris such as blood, mucus and inflammatory cells, aiding in visualization of diagnostically relevant cells—and reducing patient callbacks.1,7
100% of cells for the lab
90% of blood removed from sample1
* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916. 2. Fontaine D et al. BMJ Open. 2012;2(2):e000847. 3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279. 4. Rozemeijer K et al. BMJ. 2017;356:j504. 5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174. 6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153. 7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31
Increase abnormal cell detection
Reduce the risk of missed cases of invasive cervical cancer by choosing the BD SurePath™ Liquid-based Pap Test
- The BD SurePath™ Liquid-based Pap Test provides a 64.4% increase in HSIL+ detection compared to conventional cytology5,6
Higher disease detection rate
Lower risk of missing disease
- Using the BD SurePath™ Liquid-based Pap Test as the primary test method was associated with lower cervical cancer rates diagnosed after a normal screening sample compared to conventional cytology or ThinPrep®*4
19%
reduced risk of invasive cervical cancer following a negative sample result compared to conventional cytology4
29%
reduced risk of invasive cervical cancer following a negative sample result compared to ThinPrep®4
* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916. 2. Fontaine D et al. BMJ Open. 2012;2(2):e000847. 3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279. 4. Rozemeijer K et al. BMJ. 2017;356:j504. 5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174. 6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153. 7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31
Improve the continuum of care
The BD SurePath™ Liquid-based Pap Test can help you achieve actionable results and reduce the burden on the lab and health teams
- Up-front accuracy leads to fewer patient callbacks, which could reduce patient anxiety
- Fewer unsatisfactory results reduce the need for reprocessing samples and rescheduling patients, thus lessening the burden on the lab and nursing staff
- The BD SurePath™ ethanol-based preservative is safe for health care professionals and lab personnel & safe for transport and storage
Actionable results
Reduced burden on staff
* Results from a comprehensive, independent study representing nearly 6 million samples from over 13 years of data taken from a national screening program4
ASCUS, atypical squamous cells of undetermined significance; HSIL, high grade squamous intraepithelial lesions
1. Moriarty AT et al. Arch Patho Lab Med. 2009;133(12):1912–1916. 2. Fontaine D et al. BMJ Open. 2012;2(2):e000847. 3. Fremont-Smith M et al. Cancer. 2004; 102(5):269–279. 4. Rozemeijer K et al. BMJ. 2017;356:j504. 5. Bigras G et al. J Low Genit Tract Dis. 2003;7(3):168–174. 6. Nance KV. Diagn Cytopathol. 2007;35(3):148–153. 7. Sweeney B et al. Cancer. 2006 ;108(1) :27-31
